Theravance Biopharma, Inc. (NASDAQ: TBPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Theravance Biopharma to Participate in an Upcoming Investor Conference
Vicinitas Therapeutics Appoints Adam Hughes as Chief Scientific Officer [Yahoo! Finance]